Immuneering announces initial response data from first five IMM-1-104 patients
PremiumThe FlyImmuneering announces initial response data from first five IMM-1-104 patients
2M ago
Immuneering price target lowered to $12 from $16 at Chardan
Premium
The Fly
Immuneering price target lowered to $12 from $16 at Chardan
3M ago
Immuneering receives fast track designation for IMM-1-104 from FDA
Premium
The Fly
Immuneering receives fast track designation for IMM-1-104 from FDA
3M ago
Immuneering price target lowered to $15 from $20 at Needham
PremiumThe FlyImmuneering price target lowered to $15 from $20 at Needham
8M ago
Immuneering price target lowered to $16 from $21 at Chardan
Premium
The Fly
Immuneering price target lowered to $16 from $21 at Chardan
8M ago
Immuneering downgraded to Hold from Buy at Jefferies
Premium
The Fly
Immuneering downgraded to Hold from Buy at Jefferies
8M ago
Immuneering Appoints New Director, Advances Cancer Drug Trial
PremiumCompany AnnouncementsImmuneering Appoints New Director, Advances Cancer Drug Trial
8M ago
Immuneering announces near-term milestone expectations
Premium
The Fly
Immuneering announces near-term milestone expectations
8M ago
Immuneering announces results from Phase 1 portion of IMM-1-104 Phase 1/2a trial
Premium
The Fly
Immuneering announces results from Phase 1 portion of IMM-1-104 Phase 1/2a trial
8M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100